Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.

All protocols
recoverysubcutaneous

BPC-157 + TB-500

BPC-157 + TB-500 Recovery Stack

Written by Peptide Association Editorial TeamMedically reviewed by Ian Justl Ellis, MD, CPTLast reviewed Editorial policy

Dosing

BPC-157 250 mcg daily + TB-500 2.0 mg 2x/week near injury site.

Cycle Length

6–8 weeks

Contraindications

Active cancer is an absolute contraindication.

Notes

Most popular recovery combination in clinical practice.

BPC-157 + TB-500 is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States. This protocol reference is educational only.

This protocol is for educational purposes only. Always consult a qualified healthcare provider before starting any peptide therapy.